Current understanding of resistance to abiraterone   and enzalutamide in advanced prostate cancer.

Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
Clin Adv Hematol Oncol. 2016 May;14(5):316-9
Authors: Antonarakis ES
PMID: 27379691 [PubMed - in process]

Source: Clinical Advances in Hematology and Oncology - July 22, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research